logo

亚太地区人类胰岛素市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

亚太人胰岛素市场按产品类型（基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、生物仿制胰岛素和组合胰岛素）和地理区域进行细分。

Home Industry Reports Healthcare 亚太地区人类胰岛素市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

市场快照

Asia-Pacific Human Insulin Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 0 %
Asia-Pacific Human Insulin Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

亚太人胰岛素市场（以下简称市场研究）预计在 2019-2024 年预测期内的复合年增长率为 4.31%，预计研究市场价值将达到 70 亿美元2019 年。 

  • 糖尿病是亚太地区快速增长的慢性病之一，尤其是在中国、印度和日本等国家。由于糖尿病和肥胖症的日益流行以及该地区有利的监管情况，中国在所研究的市场中占据主导地位。
  • 遗传因素是该病迅速传播的主要原因之一。久坐不动的生活方式和肥胖是导致该疾病高发病率的其他因素。
  • 尽管胰岛素用于治疗糖尿病已有 90 多年的历史，但由于产品成本高昂，如今仍有一半以上需要胰岛素的人负担不起和无法获得它。

报告范围

亚太人胰岛素市场按产品类型（基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、生物仿制胰岛素和组合胰岛素）和地理区域进行细分。

By Product Type
Insulin (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Abasaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Admelog (Insulin Lispro)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
Asia-Pacific
Australia (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
China (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
India (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Indonesia (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Japan (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Malaysia (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Philippines (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
South Korea (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Thailand (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Vietnam (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)
Rest of Asia-Pacific (Value and Volume 2012-2024)
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Insulin Combinations
By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

Report scope can be customized per your requirements. Click here.

主要市场趋势

糖尿病人口激增

  • 亚太地区的糖尿病人口将大幅增加。糖尿病的负担正在增加，预计亚太地区将高速增长。 
  • 亚太地区在全球糖尿病市场占据主导地位，占糖尿病人口的 60%。 
  • 中国和印度的糖尿病人口最多，尤其是 2 型。中国有超过 11% 的人口患有糖尿病，而在印度，有 5% 的人口患有糖尿病。 
  • 亚太地区其他国家的医疗基础设施和利用率低下以及对这种疾病的认识不足，使该疾病的流行复杂化。此外，在这些地区，大多数病例都无法控制，甚至无法确诊，直到患者出现并发症症状。对疾病缺乏认识、营养不均衡以及医疗基础设施和利用不足等因素正在限制该地区的胰岛素市场。  
Asia-Pacific Human Insulin Market Key Trends

中国主导亚太人胰岛素市场

  • 由于庞大的患者群体和该国胰岛素生物类似药监管程序的宽松，预计中国将占据最大的市场份额，并有望在预测期内保持其主导地位。
  • 近十年来，2 型糖尿病（T2D）的发病率迅速增加，T2D 已成为中国主要的公共卫生挑战。 
  • 亚太地区的生物类似药市场有相当大的增长，中国甘李巴沙林占据了整个甘精药物市场近40%的份额。 
Asia-Pacific Human Insulin Market Growth by Region

竞争格局

  • 亚太人胰岛素市场高度整合，三大厂商占据较大市场份额。然而，许多本地公司以便宜得多的价格将生物仿制药胰岛素推向市场。
  • 近期参与者之间发生的并购有助于这些公司加强其市场占有率。
  • Cipla 已与礼来 (Eli Lilly) 合作，在印度营销和分销礼来 (Lilly) 的甘精胰岛素注射液 basaglar。
  • Sandoz 与 Gan&Lee 合作将 Gan&Lee 开发的胰岛素商业化。山德士很可能全面负责这些药物在欧盟、美国、瑞士、日本、韩国、加拿大、澳大利亚和新西兰的商业化。  
Novo Nordisk, Eli Lilly, Sanofi, Biocon, Gan & Lee, Wockhardt

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Insulin (Value and Volume 2012-2024)

        1. 5.1.1.1 Basal or Long Acting Insulins

          1. 5.1.1.1.1 Lantus (Insulin Glargine)

          2. 5.1.1.1.2 Levemir (Insulin Detemir)

          3. 5.1.1.1.3 Toujeo (Insulin Glargine)

          4. 5.1.1.1.4 Tresiba (Insulin Degludec)

          5. 5.1.1.1.5 Abasaglar (Insulin Glargine)

        2. 5.1.1.2 Bolus or Fast Acting Insulins

          1. 5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.1.2.2 Humalog (Insulin Lispro)

          3. 5.1.1.2.3 Apidra (Insulin Glulisine)

          4. 5.1.1.2.4 FIASP (Insulin Aspart)

          5. 5.1.1.2.5 Admelog (Insulin Lispro)

        3. 5.1.1.3 Traditional Human Insulins

          1. 5.1.1.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.1.3.2 Humilin

          3. 5.1.1.3.3 Insuman

        4. 5.1.1.4 Insulin Combinations

          1. 5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

          4. 5.1.1.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)

        5. 5.1.1.5 Biosimilar Insulins

          1. 5.1.1.5.1 Insulin Glargine Biosimilars

          2. 5.1.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 Asia-Pacific

        1. 5.2.1.1 Australia (Value and Volume 2012-2024)

          1. 5.2.1.1.1 Basal or Long Acting Insulins

          2. 5.2.1.1.2 Bolus or Fast Acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Biosimilar Insulins

          5. 5.2.1.1.5 Insulin Combinations

          6. 5.2.1.1.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        2. 5.2.1.2 China (Value and Volume 2012-2024)

          1. 5.2.1.2.1 Basal or Long Acting Insulins

          2. 5.2.1.2.2 Bolus or Fast Acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Biosimilar Insulins

          5. 5.2.1.2.5 Insulin Combinations

          6. 5.2.1.2.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        3. 5.2.1.3 India (Value and Volume 2012-2024)

          1. 5.2.1.3.1 Basal or Long Acting Insulins

          2. 5.2.1.3.2 Bolus or Fast Acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Biosimilar Insulins

          5. 5.2.1.3.5 Insulin Combinations

          6. 5.2.1.3.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        4. 5.2.1.4 Indonesia (Value and Volume 2012-2024)

          1. 5.2.1.4.1 Basal or Long Acting Insulins

          2. 5.2.1.4.2 Bolus or Fast Acting Insulins

          3. 5.2.1.4.3 Traditional Human Insulins

          4. 5.2.1.4.4 Biosimilar Insulins

          5. 5.2.1.4.5 Insulin Combinations

          6. 5.2.1.4.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        5. 5.2.1.5 Japan (Value and Volume 2012-2024)

          1. 5.2.1.5.1 Basal or Long Acting Insulins

          2. 5.2.1.5.2 Bolus or Fast Acting Insulins

          3. 5.2.1.5.3 Traditional Human Insulins

          4. 5.2.1.5.4 Biosimilar Insulins

          5. 5.2.1.5.5 Insulin Combinations

          6. 5.2.1.5.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        6. 5.2.1.6 Malaysia (Value and Volume 2012-2024)

          1. 5.2.1.6.1 Basal or Long Acting Insulins

          2. 5.2.1.6.2 Bolus or Fast Acting Insulins

          3. 5.2.1.6.3 Traditional Human Insulins

          4. 5.2.1.6.4 Biosimilar Insulins

          5. 5.2.1.6.5 Insulin Combinations

          6. 5.2.1.6.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        7. 5.2.1.7 Philippines (Value and Volume 2012-2024)

          1. 5.2.1.7.1 Basal or Long Acting Insulins

          2. 5.2.1.7.2 Bolus or Fast Acting Insulins

          3. 5.2.1.7.3 Traditional Human Insulins

          4. 5.2.1.7.4 Biosimilar Insulins

          5. 5.2.1.7.5 Insulin Combinations

          6. 5.2.1.7.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        8. 5.2.1.8 South Korea (Value and Volume 2012-2024)

          1. 5.2.1.8.1 Basal or Long Acting Insulins

          2. 5.2.1.8.2 Bolus or Fast Acting Insulins

          3. 5.2.1.8.3 Traditional Human Insulins

          4. 5.2.1.8.4 Biosimilar Insulins

          5. 5.2.1.8.5 Insulin Combinations

          6. 5.2.1.8.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        9. 5.2.1.9 Thailand (Value and Volume 2012-2024)

          1. 5.2.1.9.1 Basal or Long Acting Insulins

          2. 5.2.1.9.2 Bolus or Fast Acting Insulins

          3. 5.2.1.9.3 Traditional Human Insulins

          4. 5.2.1.9.4 Biosimilar Insulins

          5. 5.2.1.9.5 Insulin Combinations

          6. 5.2.1.9.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        10. 5.2.1.10 Vietnam (Value and Volume 2012-2024)

          1. 5.2.1.10.1 Basal or Long Acting Insulins

          2. 5.2.1.10.2 Bolus or Fast Acting Insulins

          3. 5.2.1.10.3 Traditional Human Insulins

          4. 5.2.1.10.4 Biosimilar Insulins

          5. 5.2.1.10.5 Insulin Combinations

          6. 5.2.1.10.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

        11. 5.2.1.11 Rest of Asia-Pacific (Value and Volume 2012-2024)

          1. 5.2.1.11.1 Basal or Long Acting Insulins

          2. 5.2.1.11.2 Bolus or Fast Acting Insulins

          3. 5.2.1.11.3 Traditional Human Insulins

          4. 5.2.1.11.4 Biosimilar Insulins

          5. 5.2.1.11.5 Insulin Combinations

          6. 5.2.1.11.6 By Company (Novo Nordisk, Sanofi, Eli Lilly, and Other Companies)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2024)

    2. 6.2 Type-2 Diabetic Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Eli Lilly

      3. 7.1.3 Sanofi

      4. 7.1.4 Biocon

      5. 7.1.5 Gan & Lee

      6. 7.1.6 Wockhardt

    2. 7.2 Company Share Analysis

      1. 7.2.1 Novo Nordisk

      2. 7.2.2 Eli Lilly

      3. 7.2.3 Sanofi

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Human Insulin Market market is studied from 2016 - 2027.

The Asia-Pacific Human Insulin Market is growing at a CAGR of 0% over the next 5 years.

Novo Nordisk, Eli Lilly, Sanofi, Biocon, Gan & Lee are the major companies operating in Asia-Pacific Human Insulin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!